Enwei Pharmaceutical Co., Ltd. (SHE:301331)
China flag China · Delayed Price · Currency is CNY
21.23
-0.80 (-3.63%)
At close: Sep 10, 2026

Enwei Pharmaceutical Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Net Income
29.6251.9437.586.3167.8101.73
Depreciation & Amortization
49.0247.4746.4834.8330.9130.5
Other Amortization
4.754.826.236.556.885.59
Loss (Gain) From Sale of Assets
-2.810.140.260.04--
Asset Writedown & Restructuring Costs
4.34.425.440.581.650.07
Loss (Gain) From Sale of Investments
-4.31-5.2-3.49-3.74-0.590.44
Other Operating Activities
1.266.123.840.35-1.56-0.52
Change in Accounts Receivable
57.55-21.12-36.43-9.67-69.8930.16
Change in Inventory
-17.6216.43-12.06-2.95.4-31.39
Change in Accounts Payable
-27.213.1612.96-27.8122.12-50.73
Operating Cash Flow
100.48109.5978.9284.0162.3587.58
Operating Cash Flow Growth
57.41%38.87%-6.06%34.73%-28.80%11.53%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Capital Expenditures
-49.82-56.38-50.23-134.05-23.56-38.21
Sale of Property, Plant & Equipment
2.950.040.340.15--
Cash Acquisitions
-0.07-0.07----
Investment in Securities
-1,693-1,694-1,018-685.5-221.5-
Other Investing Activities
1,7431,671957.37775.221.050.52
Investing Cash Flow
3.41-78.83-110.62-44.18-244.01-37.7

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Long-Term Debt Issued
--241.8---
Long-Term Debt Repaid
--11.69-48.09---
Lease Payments
-1.69-1.69-1.29---
Net Debt Issued (Repaid)
9.03-11.69193.71---
Issuance of Common Stock
10.7710.7718.36-470.75-
Repurchase of Common Stock
---70.01-33--
Common Dividends Paid
-106.98-20.78-56.96-112.22--46
Other Financing Activities
-0.99----12.28-2.41
Financing Cash Flow
-88.17-21.6985.1-145.22458.47-48.41

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Foreign Exchange Rate Adjustments
-0-00-0.030.16-0.24
Net Cash Flow
15.729.0853.41-105.41276.981.23

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
50.6653.2128.69-50.0438.849.36
Free Cash Flow Growth
459.50%85.50%---21.41%4.24%
Free Cash Flow Margin
6.13%5.91%3.53%-6.37%5.61%7.26%
Free Cash Flow Per Share
0.480.520.28-0.490.460.63
Levered Free Cash Flow
33.2674.4626.78-68.8341.2521.46
Unlevered Free Cash Flow
33.8376.0628.29-68.8341.2521.46
Free Cash Flow After Leases
48.9751.5327.39-50.0438.849.36

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Cash Income Tax Paid
75.1176.3680.8784.8658.9379.2
Change in Working Capital
18.64-0.1-37.33-40.9-42.73-50.23